It's not uncommon for patients with multiple myeloma, especially those on treatments like Pomalyst (pomalidomide) and Sarclisa (isatuximab), combined with dexamethasone (DEX), to experience low absolute neutrophil counts (ANC) and overall low white blood cell counts. These are some of the side effects associated with the... read more

It's not uncommon for patients with multiple myeloma, especially those on treatments like Pomalyst (pomalidomide) and Sarclisa (isatuximab), combined with dexamethasone (DEX), to experience low absolute neutrophil counts (ANC) and overall low white blood cell counts. These are some of the side effects associated with these medications:

1. **Pomalidomide (Pomalyst)**: Often taken with dexamethasone, pomalidomide can lead to low blood cell counts, which includes white blood cells. This can increase your risk of infections.

2. **Isatuximab (Sarclisa)**: Common side effects include neutropenia (low white blood cell count), which is a decrease in a specific type of white blood cell that is crucial for fighting infections.

These treatments impact the bone marrow's ability to produce normal blood cells, including white blood cells. It's important to monitor your blood counts regularly and discuss any significant changes with your healthcare provider. They might adjust your treatment or recommend supportive care like growth factors to help manage these side effects.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Myeloma Treatments: Risks and Benefits | MyMyelomaTeam

Sarclisa (Isatuximab-irfc) for Myeloma | MyMyelomaTeam